Is ‘Free’ The Best Price for Genzyme’s Campath in Cancer?


Published On: October 30th, 2010

The future of the drug in MS treatment has become a key component of Genzyme’s rejection of an $18.5 billion hostile takeover offer from Sanofi-Aventis as too low.

Continued here:
Is ‘Free’ The Best Price for Genzyme’s Campath in Cancer?



Loading...


Comments are closed.